BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36439183)

  • 1. Exploring the molecular mechanism of hepatitis virus inducing hepatocellular carcinoma by microarray data and immune infiltrates analysis.
    Zhang YZ; Zeb A; Cheng LF
    Front Immunol; 2022; 13():1032819. PubMed ID: 36439183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New liver cancer biomarkers: PI3K/AKT/mTOR pathway members and eukaryotic translation initiation factors.
    Golob-Schwarzl N; Krassnig S; Toeglhofer AM; Park YN; Gogg-Kamerer M; Vierlinger K; Schröder F; Rhee H; Schicho R; Fickert P; Haybaeck J
    Eur J Cancer; 2017 Sep; 83():56-70. PubMed ID: 28715695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EEF1A2 inactivates p53 by way of PI3K/AKT/mTOR-dependent stabilization of MDM4 in hepatocellular carcinoma.
    Pellegrino R; Calvisi DF; Neumann O; Kolluru V; Wesely J; Chen X; Wang C; Wuestefeld T; Ladu S; Elgohary N; Bermejo JL; Radlwimmer B; Zörnig M; Zender L; Dombrowski F; Evert M; Schirmacher P; Longerich T
    Hepatology; 2014 May; 59(5):1886-99. PubMed ID: 24285179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of hepatitis B virus replication by the phosphatidylinositol 3-kinase-akt signal transduction pathway.
    Guo H; Zhou T; Jiang D; Cuconati A; Xiao GH; Block TM; Guo JT
    J Virol; 2007 Sep; 81(18):10072-80. PubMed ID: 17609269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
    Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
    Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VCP interaction with HMGB1 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.
    Pu Z; Duda DG; Zhu Y; Pei S; Wang X; Huang Y; Yi P; Huang Z; Peng F; Hu X; Fan X
    J Transl Med; 2022 May; 20(1):212. PubMed ID: 35562734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
    Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
    Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of regulatory miRNAs of the PI3K/AKT/mTOR signaling in the pathogenesis of hepatocellular carcinoma.
    Rahmani F; Ziaeemehr A; Shahidsales S; Gharib M; Khazaei M; Ferns GA; Ryzhikov M; Avan A; Hassanian SM
    J Cell Physiol; 2020 May; 235(5):4146-4152. PubMed ID: 31663122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism.
    Tian LY; Smit DJ; Jücker M
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted inhibition of ACK1 can inhibit the proliferation of hepatocellular carcinoma cells through the PTEN/AKT/mTOR pathway.
    Wang B; Song K; Chen L; Su H; Gao L; Liu J; Huang A
    Cell Biochem Funct; 2020 Jul; 38(5):642-650. PubMed ID: 32162707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long noncoding RNA PICSAR/miR-588/EIF6 axis regulates tumorigenesis of hepatocellular carcinoma by activating PI3K/AKT/mTOR signaling pathway.
    Liu Z; Mo H; Sun L; Wang L; Chen T; Yao B; Liu R; Niu Y; Tu K; Xu Q; Yang N
    Cancer Sci; 2020 Nov; 111(11):4118-4128. PubMed ID: 32860321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
    Janku F; Kaseb AO; Tsimberidou AM; Wolff RA; Kurzrock R
    Oncotarget; 2014 May; 5(10):3012-22. PubMed ID: 24931142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
    Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
    Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.
    Samarin J; Laketa V; Malz M; Roessler S; Stein I; Horwitz E; Singer S; Dimou E; Cigliano A; Bissinger M; Falk CS; Chen X; Dooley S; Pikarsky E; Calvisi DF; Schultz C; Schirmacher P; Breuhahn K
    Hepatology; 2016 Mar; 63(3):813-26. PubMed ID: 26901106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Arenobufagin, a natural bufadienolide from toad venom, induces apoptosis and autophagy in human hepatocellular carcinoma cells through inhibition of PI3K/Akt/mTOR pathway.
    Zhang DM; Liu JS; Deng LJ; Chen MF; Yiu A; Cao HH; Tian HY; Fung KP; Kurihara H; Pan JX; Ye WC
    Carcinogenesis; 2013 Jun; 34(6):1331-42. PubMed ID: 23393227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
    Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
    Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
    El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
    Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MARCKS on Tumor-Associated Macrophages is Correlated with Immune Infiltrates and Poor Prognosis in Hepatocellular Carcinoma.
    Ren X; Ju Y; Wang C; Wei R; Sun H; Zhang Q
    Cancer Invest; 2021 Oct; 39(9):756-768. PubMed ID: 34279157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated System Pharmacology Approaches to Elucidate Multi-Target Mechanism of
    Khalid HR; Aamir M; Tabassum S; Alghamdi YS; Alzamami A; Ashfaq UA
    Molecules; 2022 Sep; 27(19):. PubMed ID: 36234758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.